Drug Trial Radar · NCT05939414
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Mar 12, 2024
Primary completion
Apr 25, 2028
Study completion Oct 3, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
Conditions
- Oligometastatic Prostate Cancer (OMPC)
Interventions
AAA617Drug
Radiopharmaceutical solution for infusion/injection
piflufolastat (18F)Drug
Provided as ready-to-use radiopharmaceutical
gallium (68Ga) gozetotide (25μg)Drug
Provided as PSMA-11 Kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)Time frame: From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death due to any cause, whichever occurs first, assessed up to approximately 30 months
Locations
144 sites in 27 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas · Recruiting
VA Greater LA Healthcare System
Los Angeles, California · Recruiting
VA Palo Alto Health Care System
Palo Alto, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
UCSF
San Francisco, California · Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Cancer Specialists of North Florida
Jacksonville, Florida · Recruiting
Woodlands Medical Specialists
Pensacola, Florida · Recruiting
Piedmont Healthcare
Atlanta, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
The Cancer Institute of Alexian Brothers
Elk Grove, Illinois · Recruiting
Unity Point Clinic
Des Moines, Iowa · Recruiting
University of Kansas Hospital
Kansas City, Kansas · Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Recruiting
East Jefferson Hospital
Metairie, Louisiana · Recruiting
University of Maryland Medical Ctr
Baltimore, Maryland · Recruiting
Johns Hopkins Kimmel Com Cancer Ctr
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Med Ctr
Boston, Massachusetts · Recruiting
BAMF Health
Grand Rapids, Michigan · Withdrawn
Profound Research LLC
Royal Oak, Michigan · Withdrawn
William Beaumont Hospital
Royal Oak, Michigan · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
St Louis University
St Louis, Missouri · Recruiting
VA St Louis Health Care System
St Louis, Missouri · Withdrawn
Wash U School of Medicine
St Louis, Missouri · Recruiting
The Urology Center PC DBA UroHealth Partners
Omaha, Nebraska · Recruiting
Memorial Sloan Kettering Cancer Ctr
New York, New York · Recruiting
Associated Med Professionals of NY
Syracuse, New York · Recruiting
Montefiore Hospital
The Bronx, New York · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
Dayton Physicians
Kettering, Ohio · Recruiting
Oregon Urology Institute
Springfield, Oregon · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Univ of Texas Southwest Med Center
Dallas, Texas · Recruiting
Rio Grande Urology
El Paso, Texas · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
Blue Ridge Cancer Center
Wytheville, Virginia · Recruiting
Novartis Investigative Site
Caba, Argentina · Recruiting
Showing 40 of 144 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.